Avenue Therapeutics (ATXI) Competitors $0.42 +0.06 (+17.06%) As of 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. MTNB, VIVS, RDHL, CNSP, DRMA, THAR, SNGX, SPRB, CMND, and REVBShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Matinas Biopharma (MTNB), VivoSim Labs (VIVS), Redhill Biopharma (RDHL), CNS Pharmaceuticals (CNSP), Dermata Therapeutics (DRMA), Tharimmune (THAR), Soligenix (SNGX), Spruce Biosciences (SPRB), Clearmind Medicine (CMND), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors Matinas Biopharma VivoSim Labs Redhill Biopharma CNS Pharmaceuticals Dermata Therapeutics Tharimmune Soligenix Spruce Biosciences Clearmind Medicine Revelation Biosciences Matinas Biopharma (NYSE:MTNB) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, MTNB or ATXI? Matinas Biopharma is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas BiopharmaN/AN/A-$22.94M-$3.86-0.25Avenue TherapeuticsN/AN/A-$10.38M-$7.49-0.06 Is MTNB or ATXI more profitable? Matinas Biopharma's return on equity of -123.06% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Avenue Therapeutics N/A -471.57%-296.50% Which has more risk and volatility, MTNB or ATXI? Matinas Biopharma has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Does the media favor MTNB or ATXI? In the previous week, Avenue Therapeutics had 17 more articles in the media than Matinas Biopharma. MarketBeat recorded 17 mentions for Avenue Therapeutics and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 beat Avenue Therapeutics' score of -0.19 indicating that Matinas Biopharma is being referred to more favorably in the media. Company Overall Sentiment Matinas Biopharma Neutral Avenue Therapeutics Neutral Do analysts prefer MTNB or ATXI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of MTNB or ATXI? 11.8% of Matinas Biopharma shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 4.6% of Matinas Biopharma shares are held by insiders. Comparatively, 1.8% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryMatinas Biopharma beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34M$815.77M$5.52B$9.41BDividend YieldN/A4.84%3.80%4.04%P/E Ratio0.021.4128.0419.84Price / SalesN/A25.49429.5399.59Price / CashN/A19.5635.8457.94Price / Book0.226.878.125.65Net Income-$10.38M-$4.17M$3.25B$258.00M7 Day Performance15.07%0.03%0.97%2.09%1 Month Performance61.85%2.12%7.36%11.13%1 Year Performance-87.68%2.14%31.31%18.40% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics2.0686 of 5 stars$0.42+17.1%N/A-89.8%$1.34MN/A0.024Trending NewsMTNBMatinas BiopharmaN/A$1.00-2.9%N/AN/A$5.09MN/A-0.2130VIVSVivoSim LabsN/A$1.94+0.0%N/AN/A$5.04M$140K-0.1920Positive NewsRDHLRedhill BiopharmaN/A$2.18-0.5%N/A-99.0%$5.00M$8.04M0.00210News CoveragePositive NewsCNSPCNS Pharmaceuticals2.0325 of 5 stars$0.88+0.1%$25.00+2,755.5%-98.4%$4.78MN/A0.005News CoverageDRMADermata Therapeutics2.4424 of 5 stars$0.73+2.7%$3.00+311.5%-65.7%$4.65MN/A-0.048THARTharimmune3.2051 of 5 stars$1.69-2.3%$17.00+905.9%-53.8%$4.50MN/A-0.212Positive NewsSNGXSoligenix2.5958 of 5 stars$1.36+7.1%N/A-80.1%$4.44M-$117.03K-0.3220Analyst ForecastSPRBSpruce Biosciences2.4633 of 5 stars$0.10+15.3%$1.75+1,597.4%-83.1%$4.35M$4.91M-0.1120Gap DownCMNDClearmind Medicine0.9055 of 5 stars$0.99+4.0%N/A-42.6%$4.22MN/A-0.90N/APositive NewsREVBRevelation Biosciences0.9566 of 5 stars$2.75-1.4%N/A-96.8%$4.21MN/A-0.0110 Related Companies and Tools Related Companies Matinas Biopharma Alternatives VivoSim Labs Alternatives Redhill Biopharma Alternatives CNS Pharmaceuticals Alternatives Dermata Therapeutics Alternatives Tharimmune Alternatives Soligenix Alternatives Spruce Biosciences Alternatives Clearmind Medicine Alternatives Revelation Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXI Stock Alerts